此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

HM16390 在晚期或转移性实体瘤中的剂量递增和扩展研究

2026年11月2日 更新者:Hanmi Pharmaceutical Company Limited

HM16390 在晚期或转移性实体瘤患者中的 I 期、开放标签、多中心、剂量递增和扩展研究

This is a First-in-Human, Phase 1, Dose-Escalation and Dose-Expansion study of HM16390, as a single agent and in combination with pembrolizumab to assess safety, tolerability, MTD, RP2D, PK, and efficacy in patients with advanced or metastatic solid tumors.

Dose-Escalation Part is planned to establish the MTD or RDs for the randomized Dose-Ranging Part. Based on the results of the Dose-Escalation Part, additional eligible subjects will be randomized 1:1 into each dose level. After a comprehensive review of available data from both Dose-Escalation Part and Dose-Ranging Part, the RDEs to be tested in the Dose-Expansion Part are determined. Dose-Expansion Part is designed to assess the potential efficacy of HM16390 as a single agent and in combination with pembrolizumab when administered at the RDEs to subjects in indication-specific expansion cohorts.

研究概览

研究类型

介入性

注册 (估计的)

292

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • California
      • Los Angeles、California、美国、90095
        • 招聘中
        • The Regents of the University of California on behalf of its Los Angeles campus
    • Massachusetts
      • Boston、Massachusetts、美国、02114
        • 招聘中
        • Massachusetts General Hospital
    • Michigan
      • Detroit、Michigan、美国、48201
        • 招聘中
        • Karmanos Cancer Institute
      • Seoul、韩国、03080
        • 招聘中
        • Seoul National University Hospital
      • Seoul、韩国、06351
        • 招聘中
        • Samsung Medical Center
      • Seoul、韩国、03722
        • 招聘中
        • Severance Hospital
      • Seoul、韩国、05505
        • 主动,不招人
        • Asan Medical Center
    • Gyeonggi-do
      • Seongnam-si、Gyeonggi-do、韩国、13620
        • 招聘中
        • Seoul National University Bundang Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Key Inclusion Criteria:

  • Have a histologically and/or cytologically confirmed advanced or metastatic solid tumor and have failed or are intolerant to standard therapy with clinical benefit.
  • Patients in the Dose-Escalation Part must have evaluable or measurable disease at baseline and the patients for Dose-Ranging and Dose-Expansion Part must have at least one measurable lesion at baseline by computed tomography (CT) or magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 assessed within 7 days before allocation or randomization.
  • Age of 18 years or older (or country's legal age of majority if the legal age was >18 years)
  • Adequate renal function.
  • Adequate hematologic function.
  • Adequate liver function.

Key Exclusion Criteria:

  • Received prior treatment with agent targeting the IL-2, IL-7, or IL-15 receptors, or related to mode of action of HM16390.
  • Known active CNS metastases and/or carcinomatous meningitis.
  • History of severe toxicities associated with a prior immunotherapy.
  • Any prior treatment-related (i.e. chemotherapy, immunotherapy, radiotherapy) clinically significant toxicities that have not resolved to Grade ≤ 1 per NCI-CTCAE version 5.0 or prior treatment-related toxicities that are clinically unstable and clinically significant at time of enrollment.
  • Has ongoing or suspected autoimmune disease.
  • Known active and clinically significant bacterial, fungal or viral infection including known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness, immunocompromised patients.
  • History of chronic liver disease or evidence of hepatic cirrhosis.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:HM16390

HM16390 Monotherapy

HM16390 will be administered subcutaneously using syringes on Day 1 of every 3-week treatment cycle

实验性的:HM16390 + pembrolizumab

HM16390 in combination with pembrolizumab

Fixed dose of pembrolizumab will be administered as an IV infusion over 30 minutes on Day 1 of every 3-week treatment cycle

其他名称:
  • 可瑞达®

HM16390 will be administered subcutaneously using syringes on Day 1 of every 3-week treatment cycle

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Incidence and nature of DLTs
大体时间:At the end of Cycle 1 (each cycle is 21 days) in Dose-Escalation Part

To evaluate safety and tolerability of HM16390 as a single agent and in combination with pembrolizumab

At the end of Cycle 1 (each cycle is 21 days) in Dose-Escalation Part
Incidence, nature, and severity of adverse events and laboratory abnormalities graded per NCI-CTCAE v5.0.
大体时间:Throughout the study until end of safety follow-up period (90 days after the last treatment)

To evaluate safety and tolerability of HM16390 as a single agent, and in combination with pembrolizumab

Throughout the study until end of safety follow-up period (90 days after the last treatment)

次要结果测量

结果测量
措施说明
大体时间
Objective response rate (ORR)
大体时间:Throughout the study until disease progression or death whichever occurs first (up to 2-3 years)

ORR will be measured as the proportion of subjects with a confirmed response of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

Throughout the study until disease progression or death whichever occurs first (up to 2-3 years)
Disease Control Rate (DCR)
大体时间:Throughout the study until disease progression or death whichever occurs first (up to 2-3 years)

DCR will be measured as the proportion of subject with confirmed CR, PR, or Stable Disease (SD) as per RECIST v1.1

Throughout the study until disease progression or death whichever occurs first (up to 2-3 years)
The maximum serum concentration (Cmax)
大体时间:Throughout the study until treatment discontinuation (up to 2-3 years)

To evaluate PK profile upon HM16390 administration

Throughout the study until treatment discontinuation (up to 2-3 years)
The time to reach Cmax (Tmax)
大体时间:Throughout the study until treatment discontinuation (up to 2-3 years)

To evaluate PK profile upon HM16390 administration

Throughout the study until treatment discontinuation (up to 2-3 years)
The area under the concentration-time curve from time 0 to the last observable concentration (AUClast)
大体时间:Throughout the study until treatment discontinuation (up to 2-3 years)

To evaluate PK profile upon HM16390 administration

Throughout the study until treatment discontinuation (up to 2-3 years)
The AUC extrapolated to infinity (AUCinf)
大体时间:Throughout the study until treatment discontinuation (up to 2-3 years)

To evaluate PK profile upon HM16390 administration

Throughout the study until treatment discontinuation (up to 2-3 years)
The AUC during the dosing interval (AUCtau)
大体时间:Throughout the study until treatment discontinuation (up to 2-3 years)

To evaluate PK profile upon HM16390 administration

Throughout the study until treatment discontinuation (up to 2-3 years)
The serum concentration at the end of the dosing interval (Ctrough)
大体时间:Throughout the study until treatment discontinuation (up to 2-3 years)

To evaluate PK profile upon HM16390 administration

Throughout the study until treatment discontinuation (up to 2-3 years)
The elimination half-life (T1/2)
大体时间:Throughout the study until treatment discontinuation (up to 2-3 years)

To evaluate PK profile upon HM16390 administration

Throughout the study until treatment discontinuation (up to 2-3 years)
The apparent volume of distribution (Vd/F)
大体时间:Throughout the study until treatment discontinuation (up to 2-3 years)

To evaluate PK profile upon HM16390 administration

Throughout the study until treatment discontinuation (up to 2-3 years)
The apparent clearance (CL/F)
大体时间:Throughout the study until treatment discontinuation (up to 2-3 years)

To evaluate PK profile upon HM16390 administration

Throughout the study until treatment discontinuation (up to 2-3 years)
Progression-free survival (PFS)
大体时间:Throughout the study until disease progression or death whichever occurs first (up to 2-3 years)

PFS will be measured from date of first treatment until date of radiographic progression as per RECIST v1.1 or until death from any cause, whichever occurs first

Throughout the study until disease progression or death whichever occurs first (up to 2-3 years)
Duration of response (DOR)
大体时间:Throughout the study until disease progression or death whichever occurs first (up to 2-3 years)

DOR will be measured as the time from initial onset of CR or PR to first radiographic progression as per RECIST v1.1 or death from any cause, whichever occurs first.

Throughout the study until disease progression or death whichever occurs first (up to 2-3 years)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年12月11日

初级完成 (估计的)

2031年7月1日

研究完成 (估计的)

2031年7月1日

研究注册日期

首次提交

2024年11月29日

首先提交符合 QC 标准的

2024年12月6日

首次发布 (实际的)

2024年12月9日

研究记录更新

最后更新发布 (实际的)

2026年11月3日

上次提交的符合 QC 标准的更新

2026年11月2日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • HM-LIL2-101
  • KEYNOTE-G39 (其他标识符:Merck & Sharp Dohme LLC)
  • MK-3475-G39 (其他标识符:Merck & Sharp Dohme LLC)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅